Top

Clinical and Translational Oncology

Published in:

01-07-2018 | Research Article

The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study

Authors: L. Yang, Z. Lv, W. Xia, W. Zhang, Y. Xin, H. Yuan, Y. Chen, X. Hu, Y. Lv, Q. Xu, X. Weng, C. Ni

Published in: Clinical and Translational Oncology | Issue 7/2018

Abstract

Purpose

Aspirin could reduce the risk of cancer metastasis. Circulating tumor cells (CTCs) are a key factor of cancer metastasis, but no evidence has revealed how aspirin affects CTCs and its epithelial–mesenchymal transition (EMT). Here, we conducted a clinical trial to investigate how aspirin affects CTCs in metastatic colorectal cancer (MCC) and breast cancer patients (MBC).

Methods

The trial is retrospective registered at clinicaltrials.gov (NCT02602938). The eligible patients are given 100 mg aspirin q.d. for 8 weeks, and CTCs are evaluated at baseline, 4 and 8 weeks for absolute number, phenotype (epithelial type, E+, mesenchymal type, M+, and biophenotypic type, B+), and vimentin expression.

Results

Data on 21 MCC and 19 MBC patients are analyzed, and it revealed that the CTC numbers decreased with aspirin treatment in MCC (p < 0.001) but not MBC (p = 0.0532); besides, ratio of E+ CTCs increased (p = 0.037) and M+ CTCs decreased at 2 months in MCC (p = 0.013), but neither the ratio of E+ or M+ CTCs changes significantly in MBC; vimentin expression of M+ CTCs is higher than E+ and B+ CTCs either in MBC or MCC patients at baseline (p < 0.01); and aspirin suppresses the vimentin expression in M+ (p = 0.002)and B+ (p = 0.006) CTCs of MCC and M+ CTCs of MBC (p = 0.004); besides it find vimentin expression in B+ (p = 0.004) or M+ (p < 0.001), CTCs are markedly decreased in patients with total CTC numbers declined.

Conclusion

Aspirin could decrease CTCs numbers and block EMT transition in MCC patients and part of MBC patients.

Available only for authorised users

Groot Koerkamp B, Rahbari NN, Buchler MW, Koch M, Weitz J. Circulating tumor cells and prognosis of patients with resectable colorectal liver metastases or widespread metastatic colorectal cancer: a meta-analysis. Ann Surg Oncol. 2013;20(7):2156–65. https://doi.org/10.1245/s10434-013-2907-8.CrossRefPubMed

Lv Q, Gong L, Zhang T, Ye J, Chai L, Ni C, et al. Prognostic value of circulating tumor cells in metastatic breast cancer: a systemic review and meta-analysis. Clin Transl Oncol Off Publ Fed Spanish Oncol Soc Natl Cancer Inst Mex. 2016;18(3):322–30. https://doi.org/10.1007/s12094-015-1372-1.CrossRef

Zhou J, Ma X, Bi F, Liu M. Clinical significance of circulating tumor cells in gastric cancer patients. Oncotarget. 2017;. https://doi.org/10.18632/oncotarget.14879.CrossRefPubMedPubMedCentral

Zheng Y, Zhang C, Wu J, Cheng G, Yang H, Hua L, et al. Prognostic value of circulating tumor cells in castration resistant prostate cancer: a meta-analysis. Urol J. 2016;13(6):2881–8.PubMed

Yu M, Bardia A, Wittner BS, Stott SL, Smas ME, Ting DT, et al. Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. Science. 2013;339(6119):580–4. https://doi.org/10.1126/science.1228522.CrossRefPubMedPubMedCentral

Wu S, Liu S, Liu Z, Huang J, Pu X, Li J, et al. Classification of circulating tumor cells by epithelial-mesenchymal transition markers. PLoS One. 2015;10(4):e0123976. https://doi.org/10.1371/journal.pone.0123976.CrossRefPubMedPubMedCentral

Roop RP, Naughton MJ, Van Poznak C, Schneider JG, Lammers PE, Pluard TJ, et al. A randomized phase II trial investigating the effect of platelet function inhibition on circulating tumor cells in patients with metastatic breast cancer. Clin Breast Cancer. 2013;13(6):409–15. https://doi.org/10.1016/j.clbc.2013.08.006.CrossRefPubMedPubMedCentral

Aktas B, Tewes M, Fehm T, Hauch S, Kimmig R, Kasimir-Bauer S. Stem cell and epithelial-mesenchymal transition markers are frequently overexpressed in circulating tumor cells of metastatic breast cancer patients. Breast Cancer Res BCR. 2009;11(4):R46. https://doi.org/10.1186/bcr2333.CrossRefPubMed

Bao B, Wang Z, Ali S, Kong D, Li Y, Ahmad A, et al. Notch-1 induces epithelial-mesenchymal transition consistent with cancer stem cell phenotype in pancreatic cancer cells. Cancer Lett. 2011;307(1):26–36. https://doi.org/10.1016/j.canlet.2011.03.012.CrossRefPubMedPubMedCentral

10.

Tsuruo T, Fujita N. Platelet aggregation in the formation of tumor metastasis. Proc Jpn Acad Ser B Phys Biol Sci. 2008;84(6):189–98.CrossRefPubMedPubMedCentral

11.

Li P, Wu H, Zhang H, Shi Y, Xu J, Ye Y, et al. Aspirin use after diagnosis but not prediagnosis improves established colorectal cancer survival: a meta-analysis. Gut. 2015;64(9):1419–25. https://doi.org/10.1136/gutjnl-2014-308260.CrossRefPubMed

12.

Ye XF, Wang J, Shi WT, He J. Relationship between aspirin use after diagnosis of colorectal cancer and patient survival: a meta-analysis of observational studies. Br J Cancer. 2014;111(11):2172–9. https://doi.org/10.1038/bjc.2014.481.CrossRefPubMedPubMedCentral

13.

Bosetti C, Rosato V, Gallus S, Cuzick J, La Vecchia C. Aspirin and cancer risk: a quantitative review to 2011. Ann Oncol Off J Eur Soc Med Oncol ESMO. 2012;23(6):1403–15. https://doi.org/10.1093/annonc/mds113.CrossRef

14.

Restivo A, Cocco IM, Casula G, Scintu F, Cabras F, Scartozzi M, et al. Aspirin as a neoadjuvant agent during preoperative chemoradiation for rectal cancer. Br J Cancer. 2015;113(8):1133–9. https://doi.org/10.1038/bjc.2015.336.CrossRefPubMedPubMedCentral

15.

Elwood PC, Morgan G, Pickering JE, Galante J, Weightman AL, Morris D, et al. Aspirin in the treatment of cancer: reductions in metastatic spread and in mortality: a systematic review and meta-analyses of published studies. PLoS One. 2016;11(4):e0152402. https://doi.org/10.1371/journal.pone.0152402.CrossRefPubMedPubMedCentral

16.

Holmes MD, Chen WY, Li L, Hertzmark E, Spiegelman D, Hankinson SE. Aspirin intake and survival after breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2010;28(9):1467–72. https://doi.org/10.1200/JCO.2009.22.7918.CrossRef

17.

Holmes MD, Olsson H, Pawitan Y, Holm J, Lundholm C, Andersson TM, et al. Aspirin intake and breast cancer survival—a nation-wide study using prospectively recorded data in Sweden. BMC Cancer. 2014;14:391. https://doi.org/10.1186/1471-2407-14-391.CrossRefPubMedPubMedCentral

18.

Cole BF, Logan RF, Halabi S, Benamouzig R, Sandler RS, Grainge MJ, et al. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J Natl Cancer Inst. 2009;101(4):256–66. https://doi.org/10.1093/jnci/djn485.CrossRefPubMedPubMedCentral

19.

Patrignani P, Patrono C. Aspirin and Cancer. J Am Coll Cardiol. 2016;68(9):967–76. https://doi.org/10.1016/j.jacc.2016.05.083.CrossRefPubMed

20.

Zhang W, Xia W, Lv Z, Ni C, Xin Y, Yang L. Liquid biopsy for cancer: circulating tumor cells, circulating free DNA or exosomes? Cell Physiol Biochem Int J Exp Cell Physiol Biochem Pharmacol. 2017;41(2):755–68. https://doi.org/10.1159/000458736.CrossRef

21.

Satelli A, Batth I, Brownlee Z, Mitra A, Zhou S, Noh H, et al. EMT circulating tumor cells detected by cell-surface vimentin are associated with prostate cancer progression. Oncotarget. 2017;8(30):49329–37. https://doi.org/10.18632/oncotarget.17632.CrossRefPubMedPubMedCentral

22.

Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P, et al. Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer. BMC Cancer. 2016;16:168. https://doi.org/10.1186/s12885-016-2192-6.CrossRefPubMedPubMedCentral

23.

Leblanc R, Peyruchaud O. Metastasis: new functional implications of platelets and megakaryocytes. Blood. 2016;128(1):24–31. https://doi.org/10.1182/blood-2016-01-636399.CrossRefPubMed

24.

Orellana R, Kato S, Erices R, Bravo ML, Gonzalez P, Oliva B, et al. Platelets enhance tissue factor protein and metastasis initiating cell markers, and act as chemoattractants increasing the migration of ovarian cancer cells. BMC Cancer. 2015;15:290. https://doi.org/10.1186/s12885-015-1304-z.CrossRefPubMedPubMedCentral

25.

Kopp HG, Placke T, Salih HR. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Can Res. 2009;69(19):7775–83. https://doi.org/10.1158/0008-5472.CAN-09-2123.CrossRef

26.

Placke T, Orgel M, Schaller M, Jung G, Rammensee HG, Kopp HG, et al. Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Can Res. 2012;72(2):440–8. https://doi.org/10.1158/0008-5472.CAN-11-1872.CrossRef

27.

Domingo E, Church DN, Sieber O, Ramamoorthy R, Yanagisawa Y, Johnstone E, et al. Evaluation of PIK3CA mutation as a predictor of benefit from nonsteroidal anti-inflammatory drug therapy in colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2013;31(34):4297–305. https://doi.org/10.1200/JCO.2013.50.0322.CrossRef

28.

Hua X, Phipps AI, Burnett-Hartman AN, Adams SV, Hardikar S, Cohen SA, et al. Timing of Aspirin and other nonsteroidal anti-inflammatory drug use among patients with colorectal cancer in relation to tumor markers and survival. J Clin Oncol Off J Am Soc Clin Oncol. 2017;. https://doi.org/10.1200/JCO.2017.72.3569.CrossRef

29.

Reimers MS, Bastiaannet E, Langley RE, van Eijk R, van Vlierberghe RL, Lemmens VE, et al. Expression of HLA class I antigen, aspirin use, and survival after a diagnosis of colon cancer. JAMA Intern Med. 2014;174(5):732–9. https://doi.org/10.1001/jamainternmed.2014.511.CrossRefPubMed

30.

De Marchi T, Foekens JA, Umar A, Martens JW. Endocrine therapy resistance in estrogen receptor (ER)-positive breast cancer. Drug Discov Today. 2016;21(7):1181–8. https://doi.org/10.1016/j.drudis.2016.05.012.CrossRefPubMed

Title: The effect of aspirin on circulating tumor cells in metastatic colorectal and breast cancer patients: a phase II trial study
Authors: L. Yang
Z. Lv
W. Xia
W. Zhang
Y. Xin
H. Yuan
Y. Chen
X. Hu
Y. Lv
Q. Xu
X. Weng
C. Ni
Publication date: 01-07-2018
Publisher: Springer International Publishing
Published in: Clinical and Translational Oncology / Issue 7/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI: https://doi.org/10.1007/s12094-017-1806-z

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 7/2018

Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients

Meta-analysis of survival benefit with postoperative chemoradiotherapy in patients of lymph node positive esophageal carcinoma

Correction to: SEOM clinical guidelines for anaplastic gliomas (2017)

Preoperative plasma fibrinogen is associated with poor prognosis in esophageal carcinoma: a meta-analysis

Efficacy of radioiodine therapy for treating 20 patients with pulmonary metastases from differentiated thyroid cancer and a meta-analysis of the current literature

SEOM–SERAM–SEMNIM guidelines on the use of functional and molecular imaging techniques in advanced non-small-cell lung cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer